Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Published:2019-03 Issue:3 Volume:41 Page:477-493.e7
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Ailawadhi Sikander,DerSarkissian Maral,Duh Mei Sheng,Lafeuille Marie-Hélène,Posner George,Ralston Stephen,Zagadailov Erin,Ba-Mancini Abbie,Rifkin Robert

Funder

Millennium Pharmaceuticals Inc

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference64 articles.

1. Novel agents in the treatment of multiple myeloma: a review about the future;Naymagon;J Hematol Oncol,2016

2. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains;Lakdawalla;Health Aff (Millwood),2015

3. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model;Blommestein;Eur J Haematol,2016

4. Economic and clinical impact of multiple myeloma to managed care;Cook;J Manag Care Pharm,2008

5. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective;Rajkumar;Blood,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States;Journal of Managed Care & Specialty Pharmacy;2023-11

2. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study;Clinical Lymphoma Myeloma and Leukemia;2023-10

3. Costs of plasmocytic myeloma therapy in the drug programme at a Regional Oncology Centre in Poland;Annals of Agricultural and Environmental Medicine;2023-08-01

4. Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study;Clinical Therapeutics;2021-11

5. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis;Expert Review of Hematology;2021-09-20